Market Cap : 4.38 B | Enterprise Value : 6.44 B | P/E (TTM) : 29.17 | P/B : 2.56 |
---|
VWR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VWR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
vs
industry |
vs
history |
||
---|---|---|---|
Cash-to-Debt | 0.06 |
96% of the 261 Companies in the Global Diagnostics & Research industry. ( Industry Median: 3.52 vs. VWR: 0.06 ) Ranked among companies with meaningful Cash-to-Debt only. |
VWR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.06 Max: 0.12 Current: 0.06 |
Equity-to-Asset | 0.32 |
85% of the 239 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.61 vs. VWR: 0.32 ) Ranked among companies with meaningful Equity-to-Asset only. |
VWR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.08 Med: 0.27 Max: 0.32 Current: 0.32 |
Debt-to-Equity | 1.27 |
87% of the 164 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.36 vs. VWR: 1.27 ) Ranked among companies with meaningful Debt-to-Equity only. |
VWR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 1.27 Med: 1.57 Max: 7.75 Current: 1.27 |
Debt-to-EBITDA | 4.74 |
84% of the 116 Companies in the Global Diagnostics & Research industry. ( Industry Median: 1.77 vs. VWR: 4.74 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
VWR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.94 Med: 4.54 Max: 9.27 Current: 4.74 |
Interest Coverage | 3.90 |
85% of the 163 Companies in the Global Diagnostics & Research industry. ( Industry Median: 76.01 vs. VWR: 3.90 ) Ranked among companies with meaningful Interest Coverage only. |
VWR'
s Interest Coverage Range Over the Past 10 Years
Min: 1.25 Med: 1.62 Max: 3.96 Current: 3.9 |
Piotroski F-Score: 6 |
|
Altman Z-Score: 1.90 |
|
Beneish M-Score: -2.51 |
|
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
vs
industry |
vs
history |
||
---|---|---|---|
Operating Margin % | 6.75 |
61% of the 242 Companies in the Global Diagnostics & Research industry. ( Industry Median: -0.59 vs. VWR: 6.75 ) Ranked among companies with meaningful Operating Margin % only. |
VWR'
s Operating Margin % Range Over the Past 10 Years
Min: 6.07 Med: 6.69 Max: 7.41 Current: 6.75 |
Net Margin % | 3.27 |
61% of the 241 Companies in the Global Diagnostics & Research industry. ( Industry Median: -2.48 vs. VWR: 3.27 ) Ranked among companies with meaningful Net Margin % only. |
VWR'
s Net Margin % Range Over the Past 10 Years
Min: 0.09 Med: 2.34 Max: 3.57 Current: 3.27 |
ROE % | 9.62 |
69% of the 242 Companies in the Global Diagnostics & Research industry. ( Industry Median: -6.75 vs. VWR: 9.62 ) Ranked among companies with meaningful ROE % only. |
VWR'
s ROE % Range Over the Past 10 Years
Min: -20.54 Med: 10.47 Max: 13.96 Current: 9.62 |
ROA % | 2.93 |
65% of the 262 Companies in the Global Diagnostics & Research industry. ( Industry Median: -4.54 vs. VWR: 2.93 ) Ranked among companies with meaningful ROA % only. |
VWR'
s ROA % Range Over the Past 10 Years
Min: 0.14 Med: 3 Max: 3.16 Current: 2.93 |
ROC (Joel Greenblatt) % | 41.91 |
81% of the 259 Companies in the Global Diagnostics & Research industry. ( Industry Median: -9.57 vs. VWR: 41.91 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
VWR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 37.56 Med: 57.31 Max: 73.39 Current: 41.91 |
3-Year Revenue Growth Rate | -90.60 |
97% of the 182 Companies in the Global Diagnostics & Research industry. ( Industry Median: 4.80 vs. VWR: -90.60 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
VWR'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: -90.7 Max: -90.6 Current: -90.6 |
3-Year EBITDA Growth Rate | -90.10 |
97% of the 178 Companies in the Global Diagnostics & Research industry. ( Industry Median: 10.10 vs. VWR: -90.10 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
VWR'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0 Med: -90.1 Max: -89.9 Current: -90.1 |
Joel Greenblatt 46,582 sh (+120.69%) Robert Olstein 506,824 sh (+17.22%) | Jim Simons 186,000 sh (-13.25%) Paul Tudor Jones 11,611 sh (-27.17%) Columbia Wanger 1,390,129 sh (-41.92%) |
Mario Gabelli 62,600 sh (New) David Dreman 1,196 sh (New) John Paulson 2,675,200 sh (New) Jim Simons 836,700 sh (+349.84%) | Paul Tudor Jones Sold Out Columbia Wanger Sold Out Joel Greenblatt Sold Out Robert Olstein 451,124 sh (-10.99%) |
Caxton Associates 13,800 sh (New) Mario Gabelli 116,819 sh (+86.61%) | David Dreman 1,196 sh (unchged) | John Paulson Sold Out Jim Simons 829,200 sh (-0.90%) Robert Olstein 364,648 sh (-19.17%) |
Caxton Associates Sold Out Robert Olstein Sold Out Mario Gabelli Sold Out David Dreman Sold Out Jim Simons Sold Out |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
---|---|---|---|---|---|---|---|---|
David Dreman | 2017-12-31 | Sold Out | 0.02% | $33.06 - $33.25 | $ 33.25 | 0% | 0 | ![]() |
Robert Olstein | 2017-12-31 | Sold Out | 1.56% | $33.06 - $33.25 | $ 33.25 | 0% | 0 | ![]() |
Mario Gabelli | 2017-12-31 | Sold Out | 0.02% | $33.06 - $33.25 | $ 33.25 | 0% | 0 | ![]() |
Robert Olstein | 2017-09-30 | Reduce -19.17% | 0.36% | $32.95 - $33.18 | $ 33.25 | 1% | 364,648 | ![]() |
Mario Gabelli | 2017-09-30 | Add 86.61% | 0.01% | $32.95 - $33.18 | $ 33.25 | 1% | 116,819 | ![]() |
John Paulson | 2017-09-30 | Sold Out | 1.2% | $32.95 - $33.18 | $ 33.25 | 1% | 0 | ![]() |
John Paulson | 2017-06-30 | New Buy | 1.2% | $27.23 - $34.05 | $ 33.25 | 7% | 2,675,200 | ![]() |
Robert Olstein | 2017-06-30 | Reduce -10.99% | 0.2% | $27.23 - $34.05 | $ 33.25 | 7% | 451,124 | ![]() |
Mario Gabelli | 2017-06-30 | New Buy | 0.01% | $27.23 - $34.05 | $ 33.25 | 7% | 62,600 | ![]() |
David Dreman | 2017-06-30 | New Buy | 0.02% | $27.23 - $34.05 | $ 33.25 | 7% | 1,196 | ![]() |
Joel Greenblatt | 2017-06-30 | Sold Out | 0.02% | $27.23 - $34.05 | $ 33.25 | 7% | 0 | ![]() |
Industry: | Medical Diagnostics & Research » Diagnostics & Research NAICS: 621511 SIC: 8099 | |
---|---|---|
Compare: | NAS:NEOG, NAS:BRKR, MIL:DIA, NAS:SYNH, NYSE:CRL, NAS:EXAS, NAS:PRAH, XTER:AFX, SHSE:603658, NAS:FMI, NAS:DXCM, BSP:DASA3, BSP:FLRY3, NAS:ICLR, TSE:4544, SHSE:603882, SZSE:300463, NAS:MYGN, SZSE:300244, NAS:QDEL » details | |
Traded in other countries: | VW1.Germany, | |
Headquarter Location: | USA |
vs
industry |
vs
history |
||
---|---|---|---|
PE Ratio | 29.17 |
62% of the 113 Companies in the Global Diagnostics & Research industry. ( Industry Median: 35.00 vs. VWR: 29.17 ) Ranked among companies with meaningful PE Ratio only. |
VWR'
s PE Ratio Range Over the Past 10 Years
Min: 19.63 Med: 26.78 Max: 72.26 Current: 29.17 |
PE Ratio without NRI | 29.17 |
63% of the 113 Companies in the Global Diagnostics & Research industry. ( Industry Median: 35.56 vs. VWR: 29.17 ) Ranked among companies with meaningful PE Ratio without NRI only. |
VWR'
s PE Ratio without NRI Range Over the Past 10 Years
Min: 19.63 Med: 26.78 Max: 72.46 Current: 29.17 |
Price-to-Owner-Earnings | 20.44 |
78% of the 76 Companies in the Global Diagnostics & Research industry. ( Industry Median: 36.75 vs. VWR: 20.44 ) Ranked among companies with meaningful Price-to-Owner-Earnings only. |
VWR'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.33 Med: 23.94 Max: 27.64 Current: 20.44 |
PB Ratio | 2.56 |
73% of the 245 Companies in the Global Diagnostics & Research industry. ( Industry Median: 4.02 vs. VWR: 2.56 ) Ranked among companies with meaningful PB Ratio only. |
VWR'
s PB Ratio Range Over the Past 10 Years
Min: 2.2 Med: 2.56 Max: 2.94 Current: 2.56 |
PS Ratio | 0.95 |
90% of the 230 Companies in the Global Diagnostics & Research industry. ( Industry Median: 3.81 vs. VWR: 0.95 ) Ranked among companies with meaningful PS Ratio only. |
VWR'
s PS Ratio Range Over the Past 10 Years
Min: 0.69 Med: 0.81 Max: 0.96 Current: 0.95 |
Price-to-Free-Cash-Flow | 19.58 |
70% of the 80 Companies in the Global Diagnostics & Research industry. ( Industry Median: 29.22 vs. VWR: 19.58 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. |
VWR'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.27 Med: 18.59 Max: 27.86 Current: 19.58 |
Price-to-Operating-Cash-Flow | 15.60 |
70% of the 97 Companies in the Global Diagnostics & Research industry. ( Industry Median: 19.94 vs. VWR: 15.60 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
VWR'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.15 Med: 14.76 Max: 21.7 Current: 15.6 |
EV-to-EBIT | 20.30 |
64% of the 118 Companies in the Global Diagnostics & Research industry. ( Industry Median: 25.06 vs. VWR: 20.30 ) Ranked among companies with meaningful EV-to-EBIT only. |
VWR'
s EV-to-EBIT Range Over the Past 10 Years
Min: 11 Med: 16.6 Max: 21.3 Current: 20.3 |
EV-to-EBITDA | 14.01 |
70% of the 132 Companies in the Global Diagnostics & Research industry. ( Industry Median: 20.75 vs. VWR: 14.01 ) Ranked among companies with meaningful EV-to-EBITDA only. |
VWR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.7 Med: 11.9 Max: 14.6 Current: 14.01 |
EV-to-Revenue | 1.39 |
86% of the 242 Companies in the Global Diagnostics & Research industry. ( Industry Median: 4.24 vs. VWR: 1.39 ) Ranked among companies with meaningful EV-to-Revenue only. |
VWR'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1 Med: 1.2 Max: 1.4 Current: 1.39 |
Current Ratio | 1.25 |
83% of the 250 Companies in the Global Diagnostics & Research industry. ( Industry Median: 2.58 vs. VWR: 1.25 ) Ranked among companies with meaningful Current Ratio only. |
VWR'
s Current Ratio Range Over the Past 10 Years
Min: 1.18 Med: 1.51 Max: 1.82 Current: 1.25 |
Quick Ratio | 0.79 |
90% of the 250 Companies in the Global Diagnostics & Research industry. ( Industry Median: 2.14 vs. VWR: 0.79 ) Ranked among companies with meaningful Quick Ratio only. |
VWR'
s Quick Ratio Range Over the Past 10 Years
Min: 0.76 Med: 1.01 Max: 1.22 Current: 0.79 |
Days Inventory | 53.43 |
61% of the 204 Companies in the Global Diagnostics & Research industry. ( Industry Median: 79.76 vs. VWR: 53.43 ) Ranked among companies with meaningful Days Inventory only. |
VWR'
s Days Inventory Range Over the Past 10 Years
Min: 20.33 Med: 44.26 Max: 53.43 Current: 53.43 |
Days Sales Outstanding | 54.37 |
65% of the 204 Companies in the Global Diagnostics & Research industry. ( Industry Median: 67.51 vs. VWR: 54.37 ) Ranked among companies with meaningful Days Sales Outstanding only. |
VWR'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.68 Med: 49.29 Max: 54.37 Current: 54.37 |
Days Payable | 56.05 |
57% of the 187 Companies in the Global Diagnostics & Research industry. ( Industry Median: 63.34 vs. VWR: 56.05 ) Ranked among companies with meaningful Days Payable only. |
VWR'
s Days Payable Range Over the Past 10 Years
Min: 50.82 Med: 54.33 Max: 56.46 Current: 56.05 |
vs
industry |
vs
history |
||
---|---|---|---|
3-Year Average Share Buyback Ratio | -995.90 |
99% of the 180 Companies in the Global Diagnostics & Research industry. ( Industry Median: -7.90 vs. VWR: -995.90 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
VWR'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -995.9 Med: -995.3 Max: 0 Current: -995.9 |
vs
industry |
vs
history |
||
---|---|---|---|
Price-to-Median-PS-Value | 1.17 |
59% of the 193 Companies in the Global Diagnostics & Research industry. ( Industry Median: 1.01 vs. VWR: 1.17 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
VWR'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.9 Med: 1.01 Max: 1.18 Current: 1.17 |
Earnings Yield (Greenblatt) % | 4.93 |
84% of the 265 Companies in the Global Diagnostics & Research industry. ( Industry Median: -0.98 vs. VWR: 4.93 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
VWR'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.7 Med: 6 Max: 9.1 Current: 4.93 |
Revenue (TTM) (Mil) $ | 4,639.90 |
---|---|
EPS (TTM) $ | 1.14 |
52-Week Range $ | 24.42 - 37.25 |
Shares Outstanding (Mil) | 131.87 |
Dec17 | Dec18 | Dec19 | |
---|---|---|---|
Revenue (Mil $) | 4,707 | 4,863 | 4,970 |
EBIT (Mil $) | |||
EBITDA (Mil $) | |||
EPS ($) | 1.93 | 1.98 | 2.08 |
EPS without NRI ($) | 1.93 | 1.98 | 2.08 |
EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | ||
Dividends per Share ($) |
|
GF Chat